As 2Gy fractionated radiation therapy (RT) is the standard of care in HNSCC, pre-clinical investigations suggest that the addition of PD-1 blockade to RT could be clinically beneficial. Here, PDCD1 is linked to head and neck squamous cell carcinoma.